Drug intelligence / Profile preview

KP-77

Development stage: Preclinical
Lead developer: KALM Therapeutics
Modality: Small Molecules

Overview

KP-77 is a chemical drug candidate initially developed by KALM Therapeutics. It is in preclinical development and targets immune system diseases, congenital disorders, and skin and musculoskeletal diseases. The primary indications under investigation are acne vulgaris, atopic dermatitis, and psoriasis. Specific details regarding its mechanism of action or molecular target have not been disclosed as of the latest available update[1].

Beyond the preview

Go deeper on KP-77.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP-77.

Explore the full profile